Loading company…
Specific Biologics develops gene editing technology for potential use in genetic diseases.
Specific Biologics develops the Dualase gene editing platform, which uses a dual-cleaving nuclease to modify DNA. It is advancing preclinical programs targeting liver, ocular and CNS diseases, as well as cystic fibrosis. Founded in 2017 and based in Toronto, Canada, the company raised venture funding in October 2023 from returning investors Lumira Ventures and adMare Bioinnovations.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in